What is the pathogenesis, clinical presentation, imaging findings, and treatment of osteosarcoma?

Osteosarcoma: Etiopathogenesis, Clinical Features, Radiological Features, and Management

Etiopathogenesis

Osteosarcoma is a primary malignant bone tumor characterized by the production of an osteoid matrix, with a heterogeneous genetic profile lacking a consistent unifying pathogenic event. 1, 2

• The tumor exhibits complex genetic alterations, with approximately 70% of patients demonstrating mutations in the tumor suppressor retinoblastoma gene (RB1) 3
• Genetic cancer syndromes predisposing to osteosarcoma include Li-Fraumeni syndrome, hereditary retinoblastoma, Rothmund-Thomson syndrome type 2, Bloom syndrome, Werner syndrome, RAPADILINO syndrome, and Diamond-Blackfan anemia 3
• The pathogenesis involves disruption of normal osteoblast production and bone biology, though the precise molecular mechanisms remain incompletely understood 1
• Genetic consultation and testing should be considered for patients with a family or personal history of bone sarcomas 3

Clinical Features

Osteosarcoma typically presents with bone pain and swelling in the metaphysis of long bones, most commonly around the knee in children and adolescents, with a bimodal age distribution peaking in the second decade and late adulthood. 3, 4

Presentation Patterns:

• Location: Predominantly affects the metaphysis of long bones around the knee; axial skeleton and craniofacial involvement occurs primarily in adults 3
• Symptoms: Bone pain is the most common manifestation, often accompanied by swelling 5
• Age distribution: Bimodal peaks in the second decade of life and late adulthood 4

Prognostic Factors:

• Adverse prognostic indicators include: 3
  • Proximal extremity or axial tumor site
  • Large tumor volume
  • Elevated serum alkaline phosphatase (ALP) or lactate dehydrogenase (LDH)
  • Detectable primary metastases (most important)
  • Poor histological response to preoperative chemotherapy
  • Older age
• Female sex is associated with better outcomes and increased chemotherapy-induced tumor necrosis 3
• Children have better outcomes than adolescents and adults 3

Laboratory Findings:

• No specific laboratory tests exist for osteosarcoma 3
• Elevated ALP and LDH correlate with adverse outcomes 3
• Serum LDH is significantly higher in patients with metastatic disease at presentation 3

Radiological Features

Initial imaging should include plain radiographs showing cortical destruction and irregular reactive bone formation, followed by MRI for local staging and chest CT for metastatic evaluation. 3

Imaging Modalities and Findings:

Plain Radiography:

• Shows cortical destruction and irregular reactive bone formation 3
• Conventional osteosarcoma typically presents with mixed radiological pattern (lytic and bone mineralization) or completely eburneous appearance 6, 7
• Aggressive periosteal reactions including sunburst pattern, Codman triangle, and soft-tissue components are frequently displayed 6
• The Bone Reporting and Data System (Bone-RADS) is valuable for stratifying risk of suspicious bone lesions 6

MRI (Preferred for Local Staging):

• Best imaging modality to define extent of lesion within bone and soft tissues 3
• Essential for detecting "skip" metastases (intramedullary tumor foci without direct contact with primary lesion) 3
• Evaluates anatomic relationships with surrounding neurovascular structures 3
• Should include entire bone and adjacent joints 3
• Advanced techniques (DCE-MRI, DWI, perfusion MRI) help characterize tumor environment and assess treatment response 6
• MRI provides the most accurate evaluation of response to neoadjuvant chemotherapy 3

CT Scanning:

• Preferred modality for evaluating bone matrix 6
• High-resolution spiral CT of thorax is mandatory for detecting pulmonary metastases 3
• Important caveat: CT scans tend to underestimate the number of pulmonary metastases and may fail to detect contralateral involvement 3

Nuclear Medicine:

• Radionuclide bone scan complemented by X-rays and/or MRI of affected areas 3
• FDG-PET/CT and/or bone scan for head-to-toe evaluation 3
• Whole-body MRI and PET/CT or PET/MRI are under evaluation for staging and treatment response 3

Variant-Specific Imaging:

• Telangiectatic osteosarcoma: Presents as purely lytic lesion with multiple fluid-fluid levels on MRI fluid-sensitive sequences 6, 7

Staging:

• The Musculoskeletal Tumor Society staging system distinguishes between low and high grades with intra- and extracompartmental extension; most osteosarcomas are classified as stage IIB 3
• UICC-TNM 6th edition represents an advancement of this system 3

Management

Curative treatment for high-grade osteosarcoma consists of surgery and chemotherapy, increasing disease-free survival from 10-20% with surgery alone to >60% with multimodal treatment. 3

Treatment Setting:

• Patients must be treated in specialized reference centers able to provide access to the full spectrum of care, ideally within prospective multi-institutional trials 3
• Pediatric and adolescent patients require surgeons with experience in age-specific reconstruction challenges 3

Surgical Management:

Principles:

• Goal is to safely remove the tumor while preserving maximum function 3
• Most patients should be considered candidates for limb salvage 3
• Surgical margins must be at least wide by Enneking's definition (complete removal including biopsy tract surrounded by unviolated cuff of normal tissue) 3
• Narrower margins (R1 and R2) are associated with increased risk of local recurrence and reduced overall survival 3
• Studies show no significant difference in survival and local recurrence rates between limb-sparing surgery and amputation, but limb-sparing surgery provides better functional outcomes 3

Special Considerations:

• Areas with suspicion of close margins should be marked on surgical specimens 3
• In cases of pathological fracture, internal fixation is contraindicated as it disseminates tumor; external splintage is recommended 3
• Pathological fracture does not necessarily require amputation; neoadjuvant chemotherapy can allow fracture hematoma to contract 3

Chemotherapy:

Standard Agents:

• Doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide are the most active agents 3
• The MAP regimen (doxorubicin/cisplatin/high-dose methotrexate) is most frequently used as front-line chemotherapy in children and young adults 3
• High-dose methotrexate can be challenging to administer in adults, particularly those >40 years 3
• Effective regimens employ several drugs over 6-12 months 3

Treatment Approach:

• Most protocols include preoperative chemotherapy, though this has not been proven to add survival benefit over postoperative chemotherapy alone 3
• The extent of histological response to preoperative chemotherapy provides important prognostic information 3
• Good histologic response to preoperative chemotherapy is associated with improved outcomes 3
• Current trials evaluate whether altering postoperative chemotherapy in poor responders improves outcomes, but benefit remains unproven 3

Important Caveats:

• High-dose methotrexate requires meticulous adherence to protocol-specific recommendations due to potential toxicity 3
• Use of growth factors for dose escalation or increased dose intensity does not improve survival 3
• Addition of muramyl tripeptide (MTP) to postoperative chemotherapy showed statistically significant advantage in overall survival in a randomized trial; following EMEA approval, it is an option for shared decision-making 3

Baseline Assessment Before Chemotherapy:

Mandatory tests include: 3

• Complete blood count and differential
• Blood group typing
• Coagulation profile
• Serum electrolytes including magnesium and phosphate
• Renal and liver function tests
• Hepatitis and HIV testing
• Echocardiogram or radionuclide ventriculography (chemotherapy can cause cardiac dysfunction)
• Audiogram (chemotherapy can cause auditory dysfunction)
• Sperm storage for male patients of reproductive age

Radiotherapy:

• Radiotherapy has a very limited role in extremity osteosarcomas 3
• Should be reserved for inoperable situations or axial locations where radical surgery is not feasible 3
• Can be indicated for palliation in inoperable sites and may provide limited survival prolongation 3

Variant-Specific Treatment:

• Low-grade central and parosteal osteosarcoma: Treated by surgery only 3
• High-grade surface, secondary, and extraosseous osteosarcoma: Follow same multimodal principles as conventional osteosarcoma 3
• Periosteal and craniofacial osteosarcoma: Role of chemotherapy not well-defined, but usually given in clinically aggressive craniofacial cases 3
• Treatment principles apply to adults up to age 60 3

Metastatic and Recurrent Disease:

Primary Metastatic Disease:

• Treatment is similar to localized disease with mandatory surgical removal of all known metastatic deposits 3
• Usually requires exploratory thoracotomy including lung palpation 3
• Approximately 30% of all patients with primary metastatic osteosarcoma and >40% of those achieving complete surgical remission become long-term survivors 3

Recurrent Disease:

• Treatment is primarily surgical with poor prognosis (long-term post-relapse survival <20%) 3
• Complete removal of all metastases must be attempted, as disease is otherwise almost universally fatal 3
• More than one-third of patients with second surgical remission survive >5 years 3
• Even patients with multiple recurrences may be cured if recurrences are resectable; repeated thoracotomies are often warranted 3
• Bilateral exploration by open thoracotomy with palpation of both lungs is recommended due to CT underestimation of metastases 3
• Role of second-line chemotherapy is much less defined than surgery with no accepted standard regimen 3

Response Evaluation:

• Best radiological method for local staging should be repeated after chemotherapy and definitive local therapy 3
• MRI provides most accurate evaluation of response 3
• Histologic response should be evaluated in resection specimen after neoadjuvant chemotherapy; degree of necrosis provides prognostic information 3

Follow-Up Protocol:

Recommended intervals from multinational trials: 3

• Every 6 weeks to 3 months in years 1-2 after diagnosis
• Every 2-4 months in years 3-4
• Every 6 months in years 5-10
• Every 6-12 months thereafter
• Each visit should include history, physical examination, and chest X-ray 3
• X-rays of primary tumor site every 4 months until end of year 4 3
• Late metastases may occur >10 years after diagnosis; no universally accepted stopping point for surveillance 3